Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | ALPL | P05186 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.56 |
| ▸ | RELA | Q04206 | 1/20 | 0.56 |
| ▸ | KDM1A | O60341 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30523857 | 1.00 | ATM (0.62) | ATMMETTL3LMNAALPLNFKB1 | |
| SCHEMBL5528604 | 1.00 | ATM (0.62) | ATMMETTL3LMNAALPLNFKB1 | |
| SCHEMBL6742383 | 0.83 | KDM4E (0.55) | LMNAALPLNFKB1NFKB2RELA | |
| SCHEMBL15677687 | 0.81 | NPSR1 (0.63) | LMNAALPLNFKB1NFKB2RELA | |
| SCHEMBL940551 | 0.81 | CTSL (0.60) | ATMMETTL3LMNANPC1KMT2A | |
| SCHEMBL941479 | 0.81 | ATM (0.60) | ATMMETTL3MEN1NPC1KMT2A | |
| Hydrochloric Acid SCHEMBL6742948 | 0.81 | KDM4E (0.54) | LMNAALPLNFKB1NFKB2RELA | |
| SCHEMBL941415 | 0.81 | ALDH1A1 (0.71) | ATMMETTL3 | |
| SCHEMBL29430148 | 0.81 | CA1 (0.50) | ATMMETTL3LMNAKDM4EKMT2A | |
| SCHEMBL15677694 | 0.80 | LMNA (0.53) | LMNAALPLNFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318782-B2 | Mitotic kinesin inhibitor | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-11-27 | — | — | US | disclosed |
| US-20110275827-A1 | Mitotic Kinesin Inhibitor | FUJIFILM CORPORATION (JP) | 2011-11-10 | — | — | US | disclosed |
| EP-1454903-B9 | Thiadiazoline derivatives for treating cancer | KYOWA HAKKO KIRIN CO LTD (JP) | 2011-10-05 | — | — | EP | disclosed |
| EP-2327702-A1 | Mitotic kinesin inhibitor | Kyowa Hakko Kirin Co., Ltd. (JP) | 2011-06-01 | — | — | EP | disclosed |
| US-7902234-B2 | Thiadiazoline derivative | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-03-08 | — | — | US | disclosed |
| US-20110004000-A1 | Mitotic Kinesin Inhibitor | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-01-06 | — | — | US | disclosed |
| US-7851635-B2 | Mitotic kinesin inhibitor | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-12-14 | — | — | US | disclosed |
| US-20100240716-A1 | THIADIAZOLINE DERIVATIVE | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-09-23 | — | — | US | disclosed |
| EP-1454903-B1 | Thiadiazoline derivatives for treating cancer | KYOWA HAKKO KIRIN CO LTD (JP) | 2010-09-08 | — | — | EP | disclosed |
| US-7759371-B2 | Thiadiazoline derivative | Kyowa Hakko Kinn Co., Ltd. (JP) | 2010-07-20 | — | — | US | disclosed |
| US-20080207706-A1 | THIADIAZOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD (JP) | 2008-08-28 | — | — | US | disclosed |
| EP-1847534-A2 | Thiadiazoline derivative | Kyowa Hakko Kogyo Co., Ltd (JP) | 2007-10-24 | — | — | EP | disclosed |
| US-20070213380-A1 | Thiadiazoline derivative | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-09-13 | — | — | US | disclosed |
| US-20070197495-A1 | ANTI-PARASITIC COMPOUNDS AND METHODS OF THEIR USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-08-23 | — | — | US | disclosed |
| US-20070155804-A1 | Mitotic kinesin inhibitor | KYOWA HAKKO KOGYO CO., LTD. OF TOKYO, JAPAN FUJI PHOTO FILM CO., LTD. KANAGAWA, JAPAN | 2007-07-05 | — | — | US | disclosed |
| EP-1734939-A1 | ANTI-PARASITIC COMPOUNDS AND METHODS OF THEIR USE | The Regents of The University of California (US) | 2006-12-27 | — | — | EP | disclosed |
| US-20060074113-A1 | Thiadiazoline derivative | KYOWA KIRIN CO., LTD. (JP) | 2006-04-06 | — | — | US | disclosed |
| EP-1616866-A1 | M-STAGE KINESIN INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
| WO-2005087211-A1 | ANTI-PARASITIC COMPOUNDS AND METHODS OF THEIR USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-09-22 | — | — | WO | disclosed |
| EP-1454903-A1 | THIADIAZOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074113-A1 | Thiadiazoline derivative | BRWD1, RB1, ARG2 | ATM 516/4885METTL3 2876/4885LMNA 3970/4885 |
| US-20070155804-A1 | Mitotic kinesin inhibitor | KIF15, KIF5A, KIF5B | ATM 648/4885METTL3 4203/4885LMNA 3410/4885 |
| US-20070213380-A1 | Thiadiazoline derivative | BRWD1, RB1, ARG2 | ATM 516/4885METTL3 2876/4885LMNA 3970/4885 |
| US-20110004000-A1 | Mitotic Kinesin Inhibitor | KIF15, KIF5A, KIF5B | ATM 648/4885METTL3 4203/4885LMNA 3410/4885 |
| US-20100240716-A1 | THIADIAZOLINE DERIVATIVE | BRWD1, WDR82, RB1 | ATM 651/4885METTL3 2787/4885LMNA 3742/4885 |
| US-20080207706-A1 | THIADIAZOLINE DERIVATIVE | BRWD1, RB1, ARG2 | ATM 516/4885METTL3 2876/4885LMNA 3970/4885 |
| US-20070197495-A1 | ANTI-PARASITIC COMPOUNDS AND METHODS OF THEIR USE | CYP51A1, TUBA3C, PIGO | ATM 4843/4885METTL3 4301/4885LMNA 933/4885 |
| US-20110275827-A1 | Mitotic Kinesin Inhibitor | KIF15, KIF5A, KIF5B | ATM 648/4885METTL3 4203/4885LMNA 3410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.